Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand

European Journal of Pharmacology

Volumn 601, Issue 1-3, 2008, Pages 1-7

  Mullins, Deborra ^a   Adham, Nika ^a   Hesk, David ^a   Wu, Yusheng ^a   Kelly, Joseph ^a   Huang, Ying ^a   Guzzi, Mario ^a   Zhang, Xiaoping ^a   McCombie, Stuart ^a   Stamford, Andrew ^a   Parker, Eric ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Insurmountable antagonism; Neuropeptide Y Y5 receptor; Receptor antagonist

Indexed keywords

ANILIDE; N [4 [(1,1 DIMETHYLBUTYL)THIO]PHENYL] 2,2 DIMETHYLPROPANAMIDE; N [[[3' FLUORO (1,1 BIPHENYL) 4 YL]AMINO]CARBONYL] N METHYL 1 (METHYLSUFONYL) 4 PIPERIDINAMINE; N [[[3',5' DIFLUORO (1,1' BIPHENYL) 4 YL]AMINO]CARBONYL] N METHYL 1 [(5 METHYL 3 PYRIDINYL)CARBONYL] 4 PIPERIDINAMINE; N [[[5 (3,5 DIFLUOROPHENYL) 2 PYRAZINYL]AMINO]CARBONYL] N METHYL 1 (METHYLSULFONYL) 4 PIPERIDINAMINE; NEUROPEPTIDE Y; NEUROPEPTIDE Y5 RECEPTOR; RADIOLIGAND; RECEPTOR BLOCKING AGENT; SCH 208639; SCH 430765; SCH 488106; SCH 500946; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING ASSAY; BINDING KINETICS; BINDING SITE; DISSOCIATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; REACTION ANALYSIS; RECEPTOR AFFINITY;

AMIDES; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; PIPERIDINES; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RATS; RECEPTORS, NEUROPEPTIDE Y; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 56949103158     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.021     Document Type: Article

References (57)

1. Balasubramaniam A. Neuropeptide Y (NPY) family of hormones: progress in the development of receptor selective agonists and antagonists. Curr. Pharm. Des. 9 (2003) 1165-1175
2. Baldock P.A., Sainsbury A., Couzens M., Enriquez R.F., Thomas G.P., Gardiner E.M., and Herzog H. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. 109 (2002) 915-921
3. Bannon A.W., Seda J., Carmouche M., Francis J.M., Norman M.H., Karbon B., and McCaleb M.L. Behavioral characterization of neuropeptide Y knockout mice. Brain Res. 868 (2000) 79-87
4. Baraban S.C. Neuropeptide Y and limbic seizures. Rev. Neurosci. 9 (1998) 117-128
5. Brady L.S., Smith M.A., Gold P.W., and Herkenham M. Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats. Neuroendocrinology 52 (1990) 441-447
6. Broqua P., Wettstein J.G., Rocher M.N., Gauthier-Martin B., Riviere P.J., Junien J.L., and Dahl S.G. Antinociceptive effects of neuropeptide Y and related peptides in mice. Brain Res. 724 (1996) 25-32
7. Cascieri M.A., Ber E., Fong T.M., Hale J.J., Tang F., Shiao L.L., Mills S.G., MacCoss M., Sadowski S., Tota M.R., and Strader C.D. Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist. Eur. J. Pharmacol. 325 (1997) 253-261
8. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
9. Clark J.T., Kalra P.S., Crowley W.R., and Kalra S.P. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115 (1984) 427-429
10. Criscione L., Rigollier P., Batzl-Hartmann C., Rueger H., Stricker-Krongrad A., Wyss P., Brunner L., Whitebread S., Yamaguchi Y., Gerald C., Heurich R.O., Walker M.W., Chiesi M., Schilling W., Hofbauer K.G., and Levens N. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J. Clin. Invest. 102 (1998) 2136-2145
11. Dean D.C., Nargund R.P., Pong S.S., Chaung L.Y., Griffin P., Melillo D.G., Ellsworth R.L., Van der Ploeg L.H., Patchett A.A., and Smith R.G. Development of a high specific activity sulfur-35-labeled sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor. J. Med. Chem. 39 (1996) 1767-1770
12. Doods H.N., Wienen W., Entzeroth M., Rudolf K., Eberlein W., Engel W., and Wieland H.A. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J Pharmacol. Exp. Ther. 275 (1995) 136-142
13. Doughty M.B., Li K., Hu L., Chu S.S., and Tessel R. Benextramine-neuropeptide Y (NPY) binding site interactions: characterization of 3H-NPY binding site heterogeneity in rat brain. Neuropeptides 23 (1992) 169-180
14. Dube M.G., Xu B., Crowley W.R., Kalra P.S., and Kalra S.P. Evidence that neuropeptide Y is a physiological signal for normal food intake. Brain Res. 646 (1994) 341-344
15. 5 receptor antagonists. US patent 6329395B1.
16. Fierens F.L., Vanderheyden P.M., De Backer J.P., and Vauquelin G. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. Eur. J. Pharmacol. 372 (1999) 199-206
17. Gerald C., Walker M.W., Criscione L., Gustafson E.L., Batzl-Hartmann C., Smith K.E., Vaysse P., Durkin M.M., Laz T.M., Linemeyer D.L., Schaffhauser A.O., Whitebread S., Hofbauer K.G., Taber R.I., Branchek T.A., and Weinshank R.L. A receptor subtype involved in neuropeptide-Y-induced food intake [see comments]. Nature 382 (1996) 168-171
18. 5 receptor antagonists. US patent 6894063B2.
19. Hansel D.E., Eipper B.A., and Ronnett G.V. Neuropeptide Y functions as a neuroproliferative factor. Nature 410 (2001) 940-944
20. Heilig M., Soderpalm B., Engel J.A., and Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 98 (1989) 524-529
21. Hu Y., Bloomquist B.T., Cornfield L.J., DeCarr L.B., Flores-Riveros J.R., Friedman L., Jiang P., Lewis-Higgins L., Sadlowski Y., Schaefer J., Velazquez N., and McCaleb M.L. Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J. Biol. Chem. 271 (1996) 26315-26319
22. Hwa J.J., Witten M.B., Williams P., Ghibaudi L., Gao J., Salisbury B.G., Mullins D., Hamud F., Strader C.D., and Parker E.M. Activation of the NPY Y5 receptor regulates both feeding and energy expenditure. Am. J. Physiol. 277 (1999) R1428-1434
23. Ishihara A., Tanaka T., Kanatani A., Fukami T., Ihara M., and Fukuroda T. A potent neuropeptide Y antagonist, 1229U91, suppressed spontaneous food intake in Zucker fatty rats. Am. J. Physiol. 274 (1998) R1500-1504
24. Ishihara A., Kanatani A., Mashiko S., Tanaka T., Hidaka M., Gomori A., Iwaasa H., Murai N., Egashira S., Murai T., Mitobe Y., Matsushita H., Okamoto O., Sato N., Jitsuoka M., Fukuroda T., Ohe T., Guan X., MacNeil D.J., Van der Ploeg L.H., Nishikibe M., Ishii Y., Ihara M., and Fukami T. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7154-7158
25. Kakui N., Tanaka J., Tabata Y., Asai K., Masuda N., Miyara T., Nakatani Y., Ohsawa F., Nishikawa N., Sugai M., Suzuki M., Aoki K., and Kitaguchi H. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor. J. Pharmacol. Exp. Ther. 317 (2006) 562-570
26. Kalra S.P., Dube M.G., Sahu A., Phelps C.P., and Kalra P.S. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 10931-10935
27. Kanatani A., Ishihara A., Asahi S., Tanaka T., Ozaki S., and Ihara M. Potent neuropeptide Y Y1 receptor antagonist, 1229U91: blockade of neuropeptide Y-induced and physiological food intake. Endocrinology 137 (1996) 3177-3182
28. Kanatani A., Ishihara A., Iwaasa H., Nakamura K., Okamoto O., Hidaka M., Ito J., Fukuroda T., MacNeil D.J., Van der Ploeg L.H., Ishii Y., Okabe T., Fukami T., and Ihara M. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem. Biophys. Res. Commun. 272 (2000) 169-173
29. Kask A., Rago L., and Harro J. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226. Br. J. Pharmacol. 124 (1998) 1507-1515
30. Lazareno S., and Birdsall N.J. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 48 (1995) 362-378
31. Liu Y.J., Shankley N.P., Welsh N.J., and Black J.W. Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action. Br. J. Pharmacol. 106 (1992) 233-241
32. Lopez-Valpuesta F.J., Nyce J.W., Griffin-Biggs T.A., Ice J.C., and Myers R.D. Antisense to NPY-Y1 demonstrates that Y1 receptors in the hypothalamus underlie NPY hypothermia and feeding in rats. Proc. R. Soc. Lond. B Biol. Sci. 263 (1996) 881-886
33. Lopez-Valpuesta F.J., Nyce J.W., and Myers R.D. NPY-Y1 receptor antisense injected centrally in rats causes hyperthermia and feeding. Neuroreport 7 (1996) 2781-2784
34. Lundberg J.M., Terenius L., Hokfelt T., Martling C.R., Tatemoto K., Mutt V., Polak J., Bloom S., and Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol. Scand. 116 (1982) 477-480
35. Marsh D.J., Hollopeter G., Kafer K.E., and Palmiter R.D. Role of the Y5 neuropeptide Y receptor in feeding and obesity [see comments]. Nat. Med. 4 (1998) 718-721
36. Matthews J.E., Jansen M., Lyerly D., Cox R., Chen W.J., Koller K.J., and Daniels A.J. Pharmacological characterization and selectivity of the NPY antagonist GR231118 (1229U91) for different NPY receptors. Regul. Pept. 72 (1997) 113-119
37. Meini S., Patacchini R., Lecci A., Quartara L., and Maggi C.A. Peptide and non-peptide bradykinin B2 receptor agonists and antagonists: a reappraisal of their pharmacology in the guinea-pig ileum. Eur. J. Pharmacol. 409 (2000) 185-194
38. Mullins D.E., Guzzi M., Xia L., and Parker E.M. Pharmacological characterization of the cloned neuropeptide Y y(6) receptor. Eur. J. Pharmacol. 395 (2000) 87-93
39. Mullins D.E., Zhang X., and Hawes B.E. Activation of extracellular signal regulated protein kinase by neuropeptide Y and pancreatic polypeptide in CHO cells expressing the NPY Y(1), Y(2), Y(4) and Y(5) receptor subtypes. Regul. Pept. 105 (2002) 65-73
40. Parker E., Van Heek M., and Stamford A. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status. Eur. J. Pharmacol. 440 (2002) 173-187
41. Parker E.M., Babij C.K., Balasubramaniam A., Burrier R.E., Guzzi M., Hamud F., Mukhopadhyay G., Rudinski M.S., Tao Z., Tice M., Xia L., Mullins D.E., and Salisbury B.G. GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists. Eur. J. Pharmacol. 349 (1998) 97-105
42. Pedrazzini T., Seydoux J., Kunstner P., Aubert J.F., Grouzmann E., Beermann F., and Brunner H.R. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor [see comments]. Nat. Med. 4 (1998) 722-726
43. Redrobe J.P., Dumont Y., St-Pierre J.A., and Quirion R. Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. Brain Res. 848 (1999) 153-166
44. Rudolf K., Eberlein W., Engel W., Wieland H.A., Willim K.D., Entzeroth M., Wienen W., Beck-Sickinger A.G., and Doods H.N. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 271 (1994) R11-13
45. Sahu A., Kalra P.S., and Kalra S.P. Food deprivation and ingestion induce reciprocal changes in neuropeptide Y concentrations in the paraventricular nucleus. Peptides 9 (1988) 83-86
46. Schild H. pAx and competitive drug antagonism. Br. J. Pharmacol. 4 (1949) 277-280
47. 5 receptor antagonists. US patent 6946476 B2.
48. Stanley B.G., and Leibowitz S.F. Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci. 35 (1984) 2635-2642
49. Tang-Christensen M., Kristensen P., Stidsen C.E., Brand C.L., and Larsen P.J. Central administration of Y5 receptor antisense decreases spontaneous food intake and attenuates feeding in response to exogenous neuropeptide Y. J. Endocrinol. 159 (1998) 307-312
50. Thiele T.E., Marsh D.J., Ste. Marie L., Bernstein I.L., and Palmiter R.D. Ethanol consumption and resistance are inversely related to neuropeptide Y levels [see comments]. Nature 396 (1998) 366-369
51. Torrens A., Mas J., Port A., Castrillo J.A., Sanfeliu O., Guitart X., Dordal A., Romero G., Fisas M.A., Sanchez E., Hernandez E., Perez P., Perez R., and Buschmann H. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity. J. Med. Chem. 48 (2005) 2080-2092
52. Vauquelin G., Morsing P., Fierens F.L., De Backer J.P., and Vanderheyden P.M. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists. Biochem. Pharmacol. 61 (2001) 277-284
53. Vettor R., Zarjevski N., Cusin I., Rohner-Jeanrenaud F., and Jeanrenaud B. Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats. Diabetologia 37 (1994) 1202-1208
54. Vezzani A., Sperk G., and Colmers W.F. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 22 (1999) 25-30
55. Wettstein J.G., Earley B., and Junien J.L. Central nervous system pharmacology of neuropeptide Y. Pharmacol. Ther. 65 (1995) 397-414
56. Wieland H.A., Engel W., Eberlein W., Rudolf K., and Doods H.N. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br. J. Pharmacol. 125 (1998) 549-555
57. Wynne K., Stanley S., McGowan B., and Bloom S. Appetite control. J. Endocrinol. 184 (2005) 291-318